Kantarjian H - Search Results

1

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H. Tanaka C, et al. Among authors: kantarjian h. Clin Pharmacol Ther. 2010 Feb;87(2):197-203. doi: 10.1038/clpt.2009.208. Epub 2009 Nov 18. Clin Pharmacol Ther. 2010. PMID: 19924121 Clinical Trial.

2

Biology and treatment of chronic myelogenous leukemia.

Giles FJ, Kantarjian HM. Giles FJ, et al. Oncology (Williston Park). 1997 Sep;11(9):1295-300; discussion 1302-10. Oncology (Williston Park). 1997. PMID: 9306419

3

Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.

Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Estey EH, et al. Among authors: kantarjian h. Blood. 1999 Oct 1;94(7):2230-5. Blood. 1999. PMID: 10498593 Free article. Clinical Trial.

4

Phase I study of liposomal daunorubicin in patients with acute leukemia.

Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Cortes J, et al. Among authors: kantarjian h. Invest New Drugs. 1999;17(1):81-7. doi: 10.1023/a:1006216001681. Invest New Drugs. 1999. PMID: 10555126 Clinical Trial.

5

Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.

Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB, Kantarjian H. Rodriguez J, et al. Among authors: kantarjian h. Clin Cancer Res. 2000 Jan;6(1):147-52. Clin Cancer Res. 2000. PMID: 10656443

6

The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.

Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. Vey N, et al. Among authors: kantarjian h. Clin Cancer Res. 2000 Feb;6(2):731-6. Clin Cancer Res. 2000. PMID: 10690560

7

Rituximab dose-escalation trial in chronic lymphocytic leukemia.

O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. O'Brien SM, et al. Among authors: kantarjian h. J Clin Oncol. 2001 Apr 15;19(8):2165-70. doi: 10.1200/JCO.2001.19.8.2165. J Clin Oncol. 2001. PMID: 11304768 Clinical Trial.

8

High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.

Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. Verstovsek S, et al. Among authors: kantarjian h. Leuk Lymphoma. 2001 Jul;42(3):511-6. doi: 10.3109/10428190109064609. Leuk Lymphoma. 2001. PMID: 11699417

9

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Talpaz M, et al. Blood. 2002 Mar 15;99(6):1928-37. doi: 10.1182/blood.v99.6.1928. Blood. 2002. PMID: 11877262 Free article. Clinical Trial.

10

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Kantarjian HM, et al. Blood. 2002 May 15;99(10):3547-53. doi: 10.1182/blood.v99.10.3547. Blood. 2002. PMID: 11986206 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,548 results

Search Page

Filters